



LUNGMAP NGS Testing Reference Page
Approved Commercial and Academic Laboratories
As of [12/17/2024]

Approved tissue-based NGS testing laboratories include:

Commercial Laboratories:

- BostonGene (Tumor Portrait Test)
- Caris Life Sciences (MI Tumor Seek Hybrid)
- Exact Sciences, Inc. (OncoExTra)
- Foundation Medicine (FoundationOne CDx)
- Genomic Testing Cooperative (Solid Tumor Profile)
- Myriad Genetics (Precise Tumor)
- NeoGenomics Laboratories (Neo Comprehensive – Solid Tumor)
- PathGroup (SmartGenomics Complete)
- Quest Diagnostics Inc. (Solid Tumor Expanded Panel)
- siParadigm Diagnostic Informatics (siPortfolio, Comprehensive NGS)
- Strata Oncology (Strata Select)
- Tempus (xT Solid Tumor)
- The Jackson Laboratory (SOMASEQ)

Academic Laboratories:

- Augusta University
- Brigham and Women's Hospital
- Cedars-Sinai Medical Center
- Children's Hospital of Philadelphia
- City of Hope National Medical Center
- Columbia University
- Dana-Farber Cancer Institute
- Fox Chase Cancer Center
- Frederick National Laboratory for Cancer Research
- Johns Hopkins Genomics
- Knight Diagnostic Laboratories at Oregon Health & Science University
- Massachusetts General Hospital
- Memorial Sloan Kettering Cancer Center
- Moffitt Cancer Center
- National Cancer Institute – Laboratory of Pathology
- Providence Genomics
- Stanford Health Care
- Texas Children's Hospital
- The University of Texas MD Anderson Cancer Center
- University of California San Francisco
- University of Chicago
- University of Colorado
- University of Illinois Chicago
- University of Michigan
- University of Washington
- Weill Cornell Medicine
- Yale University



Approved blood-based (ctDNA) NGS testing laboratories include:

Commercial Laboratories:

- Foundation Medicine (FoundationOne Liquid CDx)
- Guardant (Guardant360)
- Tempus (xF+)

Disapproved tissue-based NGS testing laboratories include:

- Guardant (Guardant360 TissueNext)
- Lahey Hospital and Medical Center (The Lahey Solid Tumor DNA NGS Test)
- NeoGenomics (NeoTYPE Lung Tumor Profile)
- Circulogene Theranostics (TumorClear NGS Panel)



Criteria for Use of a NGS-based Test NOT on the List of Approved Tests

If a potential participant has results from a CLIA, ISO/IEC or CAP approved NGS-based test that is not on the approved list above, the test may be allowable for participation in **LUNGMAP**. For inquiries regarding a test that is **not** on the approved list above, please e-mail LUNGMAPNGS@swog.org with a copy of the test results and documentation of the list of alterations included in the test (See instructions in **LUNGMAP** Section 15.4).

Acceptable NGS testing reports must contain evidence of successful testing for the presence or absence of the following tumor genomic alterations:

- ALK rearrangement/fusion
- BRAF V600E mutation
- BRAF other mutation
- CUL3 mutation
- EGFR exon 19 deletion
- EGFR exon 20 insertion
- EGFR exon 21 L858R mutation
- EGFR other mutation
- ERBB2 (HER2) amplification/copy number gain
- ERBB2 (HER2) mutation
- KEAP1 mutation
- KRAS G12C mutation
- KRAS other mutation
- MET amplification/copy number gain
- MET exon 14 skipping mutation/splice site alteration
- MET other mutation
- NFE2L2 mutation
- NTRK1 rearrangement/fusion
- NTRK2 rearrangement/fusion
- NTRK3 rearrangement/fusion
- RET rearrangement/fusion
- ROS1 rearrangement/fusion
- STK11 mutation
- TP53 mutation

Data will be collected on the **LUNGMAP** Genomic Alterations Form in Rave. Please note that this list may not be exhaustive of the full set of required alterations.